Filing identity and period
The supplied filing is PharmAthene, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2013, not a filing under the name Altimmune, Inc. This summary reflects the registrant and figures shown in the supplied document.
PharmAthene was a biodefense biopharmaceutical company developing medical countermeasures, with revenue primarily from U.S. government contracts. Results cover the three and nine months ended September 30, 2013, compared with the same 2012 periods.
Financial performance and position
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Contract revenue | $3.49 million | $6.70 million | $14.26 million | $19.16 million |
| Operating expenses | $6.69 million | $8.49 million | $20.03 million | $24.00 million |
| Operating loss | $3.20 million | $1.79 million | $5.77 million | $4.84 million |
| Net loss | $3.95 million | $0.21 million | $7.29 million | $3.65 million |
| Net loss per share | $0.08 | $0.00 | $0.15 | $0.08 |
The filing does not present a conventional gross-profit figure or gross margin. Cash and cash equivalents were $15.94 million at September 30, 2013, versus $12.70 million at December 31, 2012. Current assets were $17.77 million and current liabilities $5.41 million. Total assets were $20.62 million; total liabilities were $9.27 million.
For the first nine months, operating cash use was $0.91 million, investing cash use was $0.08 million, and financing provided $4.24 million, including net proceeds from stock sales. Cash increased $3.24 million. The company had about $2.00 million of term-loan principal outstanding, secured by substantially all assets, and no amount drawn on its revolving facility; approximately $0.7 million was available to draw. Contractual obligations listed totaled $12.24 million, including leases, research and development agreements, and term-loan principal.
Changes versus comparable periods
- Revenue fell 47.8% in Q3 and 25.5% for the nine-month period. SparVax revenue declined as development activity slowed following an FDA clinical hold imposed in August 2012; the hold was lifted in May 2013. rBChE revenue declined in Q3 but increased for the nine-month period. Valortim revenue was nil in the 2013 periods shown.
- Q3 operating loss widened despite lower operating expenses, as the revenue decline exceeded the expense reduction. Nine-month operating loss also increased.
- Q3 net loss rose substantially, in part reflecting a $0.63 million derivative fair-value loss and the absence of the prior-year $1.23 million foreign-currency translation gain recognized in earnings. For nine months, derivative remeasurement produced a $1.18 million loss in 2013 versus a $0.34 million gain in 2012.
- Research and development expense fell 49% in Q3 and 24% over nine months. Nine-month 2013 expense included approximately $0.5 million received in settlement of a vendor lawsuit. Q3 general and administrative expense rose 25%, mainly due to merger transaction costs.
- Cash rose from year-end, supported primarily by equity issuance. Shares issued and outstanding increased to 52.30 million from 48.35 million at December 31, 2012.
Outlook, significant developments, and risks
- The company expected SparVax Phase 2 work to generate revenue and costs in Q4 2013 and through 2014 under an extended BARDA contract. A partial federal government shutdown from October 1–16 temporarily suspended work, potentially reducing Q4 revenue and related costs, with delayed work expected in future periods. Management cautioned that future program revenue could be lower without new government contracts or orders.
- Management stated that operating cash flow had historically been negative and that additional financing would likely be needed. The existing at-the-market equity offering could not be used while the proposed merger agreement remained in effect. No specific cash-runway estimate or earnings guidance is provided.
- The proposed Theraclone Sciences merger, announced July 31, 2013, was pending shareholder approvals and other closing conditions. The SEC made the S-4 effective October 29, 2013; a PharmAthene shareholder meeting was scheduled for December 3, 2013. The proposed transaction contemplated roughly equal ownership of the combined company on the defined fully diluted basis.
- The companies were negotiating a non-binding proposal for a $15 million secured credit facility to refinance their existing facilities upon merger closing. Final financing terms and lender consents were not assured; merger closing without replacement financing could require repayment of existing debt and materially reduce available cash.
- In SIGA litigation, the Delaware Supreme Court affirmed a breach-of-contract finding but reversed the prior remedy and remanded the case. PharmAthene had no current recorded receivable or established financial interest in SIGA’s Arestvyr sales and could receive no proceeds. The outcome, timing, and any eventual recovery remained uncertain.
- Key risks included dependence on U.S. government funding and contracts, government termination or suspension rights, clinical and regulatory uncertainty, the need for further financing, dilution, merger execution and integration risks, and potential volatility in derivative liabilities. The filing reports effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor facts to verify
- Confirm the issuer: the supplied document names PharmAthene, Inc.; establish whether this is the intended company and period before relying on the figures.
- Track merger approvals, closing conditions, lender consents, and whether the proposed replacement credit facility was finalized and funded.
- Monitor BARDA contract activity, the timing and financial effects of resumed SparVax work, and any new government awards or funding changes.
- Follow the SIGA remand proceedings and distinguish potential litigation recovery from recognized assets or dependable cash flows.
- Assess liquidity and dilution, including the restricted equity offering, debt repayments, derivative-warrant remeasurement, and contractual commitments.